CliffBio
biologic

Glassia

Alpha-1-Proteinase Inhibitor (Human)

Loss of exclusivityFebruary 2037projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameGlassia
Active ingredientAlpha-1-Proteinase Inhibitor (Human)
Strength5G
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2025
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Glassia patent cliff — loss of exclusivity February 2037 | CliffBio